Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence

May 8th, 2012 | Posted by admin in Clinical Trials | Recurrent Tumor

Avastin ®, a drug that starves cancer cells, is usually administered intravenously when a GBM tumor recurs. The Westchester Brain Tumor Program is trying to increase the drug’s effectiveness by applying it directly to the tumor site right after the recurrent tumor is removed. This is the first time this protocol has been used anywhere. Sponsored by the Westchester Neuroscience Research Foundation .[OR IS IT THE WBTP?}


Key Eligibility Criteria:
Patients must be:

  • At least 18 years old
  • Have recurrent Glioblastoma
  • At least 12 weeks expected survival (KPS>60)
  • Able and willing to participate

Helpful links: